{"id":"https://openalex.org/W4282968097","doi":"https://doi.org/10.1158/1538-7445.am2022-6240","title":"Abstract 6240: A phase 1 study of selective PI3K\u03b3 inhibitor ZX-4081 in patients with advanced solid tumors","display_name":"Abstract 6240: A phase 1 study of selective PI3K\u03b3 inhibitor ZX-4081 in patients with advanced solid tumors","alternate_titles":[],"publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282968097","doi":"https://doi.org/10.1158/1538-7445.am2022-6240"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-6240","doi":"https://doi.org/10.1158/1538-7445.am2022-6240","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-6240","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4282968097"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101820861","display_name":"Xiaoli Qin","orcid":"https://orcid.org/0000-0002-2027-7184","observed_orcids":["https://orcid.org/0000-0002-2027-7184"]},"institutions":[{"id":"https://openalex.org/I4405267336","display_name":"Nanjing Zenshine Pharmaceuticals Co., Ltd. (China)","ror":"https://ror.org/028yg4t84","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267336"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xiaoli Qin","raw_affiliation_strings":["1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China","institution_ids":["https://openalex.org/I4405267336"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Edgar Bautista","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267336","display_name":"Nanjing Zenshine Pharmaceuticals Co., Ltd. (China)","ror":"https://ror.org/028yg4t84","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267336"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Edgar Bautista","raw_affiliation_strings":["1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China","institution_ids":["https://openalex.org/I4405267336"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100444787","display_name":"Yingying Li","orcid":"https://orcid.org/0000-0003-1184-9475","observed_orcids":["https://orcid.org/0000-0003-1184-9475"]},"institutions":[{"id":"https://openalex.org/I4405267336","display_name":"Nanjing Zenshine Pharmaceuticals Co., Ltd. (China)","ror":"https://ror.org/028yg4t84","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267336"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ying-ying Li","raw_affiliation_strings":["1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China","institution_ids":["https://openalex.org/I4405267336"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100422226","display_name":"Xiaomin Li","orcid":"https://orcid.org/0000-0002-0051-3354","observed_orcids":["https://orcid.org/0000-0002-0051-3354"]},"institutions":[{"id":"https://openalex.org/I4405267336","display_name":"Nanjing Zenshine Pharmaceuticals Co., Ltd. (China)","ror":"https://ror.org/028yg4t84","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267336"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xiaomin Li","raw_affiliation_strings":["1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China","institution_ids":["https://openalex.org/I4405267336"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101996346","display_name":"Zhiyuan Peng","orcid":"https://orcid.org/0000-0002-1302-914X","observed_orcids":["https://orcid.org/0000-0002-1302-914X"]},"institutions":[{"id":"https://openalex.org/I4405267336","display_name":"Nanjing Zenshine Pharmaceuticals Co., Ltd. (China)","ror":"https://ror.org/028yg4t84","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267336"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhiyuan Peng","raw_affiliation_strings":["1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China","institution_ids":["https://openalex.org/I4405267336"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Deming Kong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267336","display_name":"Nanjing Zenshine Pharmaceuticals Co., Ltd. (China)","ror":"https://ror.org/028yg4t84","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267336"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Deming Kong","raw_affiliation_strings":["1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China","institution_ids":["https://openalex.org/I4405267336"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100706420","display_name":"Jinfu Yang","orcid":"https://orcid.org/0000-0001-5037-0745","observed_orcids":["https://orcid.org/0000-0001-5037-0745"]},"institutions":[{"id":"https://openalex.org/I4405267336","display_name":"Nanjing Zenshine Pharmaceuticals Co., Ltd. (China)","ror":"https://ror.org/028yg4t84","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267336"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jinfu Yang","raw_affiliation_strings":["1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China","institution_ids":["https://openalex.org/I4405267336"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108838471","display_name":"Xiaolin Hao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267336","display_name":"Nanjing Zenshine Pharmaceuticals Co., Ltd. (China)","ror":"https://ror.org/028yg4t84","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267336"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xiaolin Hao","raw_affiliation_strings":["1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Zenshine Pharmaceuticals, Co. Ltd, Nanjing, China","institution_ids":["https://openalex.org/I4405267336"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405267336"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"6240","last_page":"6240"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pi3kgamma-inhibitors","display_name":"PI3K\u03b3 inhibitor","score":0.9800000190734863},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9020000100135803},{"id":"https://openalex.org/keywords/myeloid-cell-activation","display_name":"myeloid cell activation","score":0.5519999861717224},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7599999904632568},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.7480000257492065},{"id":"https://openalex.org/keywords/m1-like-macrophages","display_name":"M1-like macrophages","score":0.9169999957084656},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.8389999866485596},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.753000020980835},{"id":"https://openalex.org/keywords/4t1-breast-cancer-model","display_name":"4T1 breast cancer","score":0.7369999885559082},{"id":"https://openalex.org/keywords/ct26-cells","display_name":"CT26 cells","score":0.8529999852180481},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7160000205039978},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8840000033378601},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8309999704360962},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4490000009536743}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7706617116928101},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6006969809532166},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5657961964607239},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.47275763750076294},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4700079560279846},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36173105239868164},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3410390019416809},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.24350714683532715},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.15087038278579712},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.1090146005153656},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0634603202342987}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-6240","doi":"https://doi.org/10.1158/1538-7445.am2022-6240","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-6240","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4282938459","https://openalex.org/W3177669868","https://openalex.org/W3180556954","https://openalex.org/W2954186373","https://openalex.org/W3092328600","https://openalex.org/W2378003235","https://openalex.org/W2741438611","https://openalex.org/W2548548248","https://openalex.org/W2397170911","https://openalex.org/W4393989027"],"abstract_inverted_index":{"Abstract":[0],"ZX-4081":[1,119,165,219,264,286,318,335,364,376,432,466],"is":[2,31,94,144,423],"a":[3,38,95,168,404],"highly":[4],"selective":[5,463],"PI3K\u03b3":[6,15,30,464],"inhibitor":[7,465],"with":[8,125,175,293,303,469],"an":[9],"IC50":[10],"of":[11,43,48,64,115,132,157,170,263,285,317,325,356,406,417,420,431,462,476],"1.5":[12],"nM":[13],"for":[14,232,480],"and":[16,25,36,50,52,70,77,84,111,137,151,185,203,228,241,305,319,337,366,397,400,409,438],"1000-fold":[17],"selectivity":[18],"over":[19],"the":[20,81,106,148,188,214,275,315,323,354,414,427,477],"other":[21],"isoforms":[22],"(\u03b1,":[23],"\u03b2,":[24],"\u03b4)":[26],"in":[27,34,41,53,80,120,123,167,205,206,213,243,254,259,291,301,350,361,407,410,467],"cell-based":[28],"assays.":[29],"predominantly":[32],"expressed":[33],"leukocytes":[35],"plays":[37],"critical":[39],"role":[40],"activation":[42],"myeloid":[44],"cells":[45,328,332],"at":[46,187,221,287],"sites":[47],"inflammation":[49],"tumorigenesis,":[51],"lymphocyte":[54],"recruitment":[55],"into":[56],"tumor":[57,68,82,198,236,267,378,382],"microenvironment.":[58],"Previous":[59],"studies":[60,373],"reported":[61],"that":[62,314,375],"blockade":[63],"PI3K\u03b3-mediated":[65],"signaling":[66],"limits":[67],"growth":[69,237,268,379],"metastasis":[71],"by":[72,238,380],"activating":[73],"CD8+":[74,326],"T":[75,327,331],"cell":[76,199,208],"M1-like":[78,357],"macrophage":[79,387],"milieu,":[83],"thereby":[85],"overcome":[86],"resistance":[87],"to":[88,104,146,172,179,271,329,334,358,363,389],"immune":[89],"checkpoint":[90],"inhibitors.":[91],"ZX-4081-101":[92],"(NCT05118841)":[93],"phase":[96,153,459],"1":[97,141,460],"first-in-human,":[98],"open-label,":[99],"multi-center,":[100],"multiple-dose":[101],"ascending":[102],"study":[103,130,461],"investigate":[105],"safety,":[107,149,182,435],"tolerability,":[108,150,183,436],"pharmacokinetics,":[109,437],"pharmacodynamics,":[110],"preliminary":[112],"antitumor":[113],"activity":[114,166],"twice":[116],"daily":[117],"oral":[118],"28-day":[121],"cycles":[122],"patients":[124,174,468],"advanced":[126,176,470],"solid":[127,177,197,471],"tumors.":[128],"The":[129,258],"consists":[131],"2":[133,154,160],"parts,":[134],"Dose":[135,138],"Escalation":[136],"Expansion.":[139],"Part":[140,159],"dose":[142,155,161],"escalation":[143],"designed":[145],"determine":[147],"recommended":[152],"(RP2D)":[156],"ZX-4081.":[158,418],"expansion":[162],"will":[163],"evaluate":[164],"cohort":[169],"up":[171],"40":[173],"tumors":[178,472],"obtain":[180],"additional":[181],"PK":[184],"PD":[186],"RP2D":[189],"dose.":[190],"ZX-4081didn\u2019t":[191],"show":[192],"significant":[193],"inhibitory":[194,261],"effects":[195],"on":[196,265,274,433],"lines":[200],"including":[201],"4T1":[202,215,266],"CT-26":[204],"vitro":[207,408],"proliferation":[209],"assay.":[210],"In":[211,279],"contrast,":[212],"syngeneic":[216,281],"mouse":[217,276,282],"model,":[218,283],"treatment":[220,256,321,340,343,369],"25":[222],"mg/kg":[223,226,230,289],"BID,":[224],"50":[225,229],"QD,":[227],"BID":[231,290],"28":[233],"days":[234],"reduced":[235],"34.6%,":[239],"21.2%,":[240],"44.1%":[242],"size,":[244],"respectively":[245],"(p<":[246],"0.0001).":[247],"No":[248],"body":[249],"weight":[250],"loss":[251],"was":[252,269,296],"observed":[253],"all":[255],"groups.":[257,309,341,370],"vivo":[260,411],"effect":[262],"attributed":[270],"its":[272,434],"enhancement":[273],"anti-tumor":[277],"immunity.":[278,392],"CT26":[280],"TGI":[284],"5":[288],"combination":[292,316,421],"anti-PD1":[294,306,320,338,367],"antibody":[295,307],"80.6%":[297],"(p":[298],"value":[299],"<0.01)":[300],"comparison":[302,362],"vehicle":[304],"alone":[308,336,339,365,368],"Flow":[310],"Cytometry":[311],"analysis":[312],"illustrated":[313],"increased":[322,353],"ratio":[324,355],"regulatory":[330],"relative":[333],"Combination":[342],"also":[344],"decreased":[345],"M2-like":[346,359],"macrophages":[347,360],"(CD206+MHCII-)":[348],"proportion":[349],"macrophages,":[351],"consequently":[352],"Overall,":[371],"our":[372],"suggest":[374],"inhibits":[377],"reprogramming":[381],"microenvironment":[383],"via":[384],"impairing":[385],"PI3K\u03b3-AKT-mediated":[386],"polarization":[388],"enhance":[390],"anti-cancer":[391],"Its":[393],"absorption,":[394],"distribution,":[395],"metabolism,":[396],"excretion":[398],"(ADME)":[399],"safety":[401],"profile,":[402],"through":[403],"series":[405],"studies,":[412],"support":[413],"clinical":[415,429],"development":[416],"Inclusion":[419],"therapy":[422],"planned":[424],"after":[425],"obtaining":[426],"initial":[428],"assessment":[430],"pharmacodynamics.":[439],"Citation":[440],"Format:":[441],"Xiaoli":[442],"Qin,":[443],"Edgar":[444],"Bautista,":[445],"Ying-ying":[446],"Li,":[447,449],"Xiaomin":[448],"Zhiyuan":[450],"Peng,":[451],"Deming":[452],"Kong,":[453],"Jinfu":[454],"Yang,":[455],"Xiaolin":[456],"Hao.":[457],"A":[458],"[abstract].":[473],"In:":[474],"Proceedings":[475],"American":[478],"Association":[479],"Cancer":[481,492],"Research":[482],"Annual":[483],"Meeting":[484],"2022;":[485],"2022":[486],"Apr":[487],"8-13.":[488],"Philadelphia":[489],"(PA):":[490],"AACR;":[491],"Res":[493],"2022;82(12_Suppl):Abstract":[494],"nr":[495],"6240.":[496]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4282968097","counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-06-17T00:00:00"}
